Search Result

Results for "

c-Kit inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Kit (96) ADC Payload (1) Akt (4) Anaplastic lymphoma kinase (ALK) (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (38) Aurora Kinase (2) Autophagy (28) Bcr-Abl (16) c-Fms (19) c-Met/HGFR (4) Casein Kinase (1) Caspase (1) CDK (1) Checkpoint Kinase (Chk) (1) Discoidin Domain Receptor (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (3) EGFR (6) Endogenous Metabolite (1) ERK (2) FAK (2) Ferroptosis (4) FGFR (20) FLT3 (28) Glycosidase (1) IKK (2) Isotope-Labeled Compounds (8) JAK (1) Microtubule/Tubulin (2) Mitosis (1) MMP (1) NAMPT (2) NO Synthase (3) p38 MAPK (1) PDGFR (68) PDK-1 (2) Pim (1) PKA (1) PKC (4) Pyk2 (1) RAD51 (3) Raf (4) Reference Standards (26) RET (6) SARS-CoV (6) Src (9) STAT (1) Syk (1) Trk Receptor (1) VEGFR (47)
By Research Areas:	Cancer (111) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (16) Metabolic Disease (2) Neurological Disease (3)

By Targets:

c-Kit (96)

ADC Payload (1)

Akt (4)

Anaplastic lymphoma kinase (ALK) (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (38)

Aurora Kinase (2)

Autophagy (28)

Bcr-Abl (16)

c-Fms (19)

c-Met/HGFR (4)

Casein Kinase (1)

Caspase (1)

CDK (1)

Checkpoint Kinase (Chk) (1)

Discoidin Domain Receptor (1)

Drug Metabolite (1)

Drug-Linker Conjugates for ADC (3)

EGFR (6)

Endogenous Metabolite (1)

ERK (2)

FAK (2)

Ferroptosis (4)

FGFR (20)

FLT3 (28)

Glycosidase (1)

IKK (2)

Isotope-Labeled Compounds (8)

JAK (1)

Microtubule/Tubulin (2)

Mitosis (1)

MMP (1)

NAMPT (2)

NO Synthase (3)

p38 MAPK (1)

PDGFR (68)

PDK-1 (2)

Pim (1)

PKA (1)

PKC (4)

Pyk2 (1)

RAD51 (3)

Raf (4)

Reference Standards (26)

RET (6)

SARS-CoV (6)

Src (9)

STAT (1)

Syk (1)

Trk Receptor (1)

VEGFR (47)

By Research Areas:

Cancer (111)

Cardiovascular Disease (3)

Infection (4)

Inflammation/Immunology (16)

Metabolic Disease (2)

Neurological Disease (3)

127

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: c-Kit

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16749

Pexidartinib Maximum Cited Publications 145 Publications Verification PLX-3397	c-Fms c-Kit Apoptosis	Cancer
Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and *c-Kit* inhibitor, with IC₅₀s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 .

HY-15463

Imatinib 115+ Cited Publications STI571; CGP-57148B	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and *c-kit* kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-10208

Pazopanib 20+ Cited Publications GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, *c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-50946

Imatinib Mesylate 115+ Cited Publications STI571 Mesylate; CGP-57148B Mesylate	c-Kit Bcr-Abl PDGFR Autophagy	Infection Neurological Disease Inflammation/Immunology Cancer
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits *c-Kit, Bcr-Abl, and PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-16749A

Pexidartinib hydrochloride Maximum Cited Publications 145 Publications Verification PLX-3397 hydrochloride	c-Fms c-Kit Apoptosis	Cancer
Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and *c-Kit* inhibitor, with IC₅₀s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .

HY-10514

BX795 35+ Cited Publications	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of PDK1, with an IC₅₀ of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

HY-136256

Vimseltinib DCC-3014	c-Fms c-Kit	Cancer
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and *c-Kit* dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC₅₀s of <0.01 μM and 0.1-1 μM, respectively . Vimseltinib has certain oral bioavailability .

HY-13024

Rebastinib 10+ Cited Publications DCC-2036	Bcr-Abl FLT3 Src Apoptosis	Cancer
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1 ^WT and Abl1 ^T315I with IC₅₀s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.

HY-10209

Masitinib 5+ Cited Publications AB1010	c-Kit PDGFR Src FGFR FAK Apoptosis	Cancer
Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of *c-Kit* (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-10209A

Masitinib mesylate 5+ Cited Publications AB-1010 mesylate	c-Kit PDGFR Src FGFR Apoptosis	Cancer
Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of *c-Kit* (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-10205

Cediranib 10+ Cited Publications AZD2171	VEGFR Autophagy PDGFR	Infection Neurological Disease Inflammation/Immunology Cancer
Cediranib (AZD2171) is a highly potent, orally available and blood-brain barrier permeability VEGFR tyrosine kinase inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-132166

Velzatinib 1 Publications Verification M4205; IDRX-42	c-Kit PDGFR c-Fms FLT3 Src	Cancer
Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, *c-Kit, FLT3, and LCK, with an IC₅₀*s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models .

HY-10527

Telatinib 1 Publications Verification Bay 57-9352	c-Kit PDGFR VEGFR	Cancer
Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and *c-Kit* with IC₅₀s of 6, 4, 15 and 1 nM, respectively.

HY-13904

Flumatinib 3 Publications Verification HHGV678	Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and *c-Kit* with IC₅₀s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .

HY-12009

Pazopanib Hydrochloride 20+ Cited Publications GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, *c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-108713

Famitinib SHR1020	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of *c-kit, VEGFR-2* and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-156619

Labuxtinib EVT-8565072; THB335	c-Kit PDGFR	Metabolic Disease Inflammation/Immunology
Labuxtinib (EVT-8565072; THB335) is a potent dual inhibitor of *c-Kit* and PDGFR. Labuxtinib exhibits potent inhibitory activity against wild-type c-Kit (IC₅₀ = 0.005 μM). Labuxtinib inhibits SCF-dependent and PDGF-dependent cell proliferation, and blocks the proliferation of cells dependent on c-Kit or PDGFR signaling pathways. In animal models of skin allergy, Labuxtinib depletes skin mast cells and significantly alleviates anaphylactic shock responses. Labuxtinib can be used in research on mast cell-related diseases, respiratory diseases, inflammatory diseases, fibrotic diseases, metabolic diseases, and other related conditions .

HY-10251

BMS-599626 3 Publications Verification AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-10408

Ki20227 4 Publications Verification	c-Fms VEGFR c-Kit PDGFR	Inflammation/Immunology
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), *c-Kit* (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .

HY-15240

c-Kit-IN-1 1 Publications Verification	c-Kit c-Met/HGFR	Cancer
c-Kit-IN-1 is a potent inhibitor of *c-Kit* and c-Met with IC₅₀s of <200 nM.

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-109190

Seralutinib 2 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

HY-10207

Dovitinib lactate 10+ Cited Publications CHIR-258 lactate; TKI-258 lactate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, *c-Kit, FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-10202

Tandutinib 5 Publications Verification MLN518; CT53518	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits *c-Kit* and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .

HY-13894

Tyrphostin AG1296 3 Publications Verification AG1296	PDGFR c-Kit FLT3 Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC₅₀ of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC₅₀ in the micromolar range .

HY-10206

Amuvatinib 5+ Cited Publications MP470; HPK 56	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis	Cancer
Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant *c-Kit, PDGFRα, Flt3, c-Met* and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-124526

Chiauranib Ibcasertib; CS2164	PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and *c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀* values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-101443

ISCK03 5+ Cited Publications	c-Kit	Inflammation/Immunology
ISCK03 is a *SCF/c-Kit* and CD117-specific inhibitor. ISCK03 significantly inhibits c-Kit phosphorylation at 10 μM .

HY-112802

AZD3229	c-Kit	Cancer
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC₅₀ value of 223.3 nM .

HY-13049

Cediranib maleate 10+ Cited Publications AZD-2171 maleate	VEGFR Autophagy PDGFR	Cancer
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-13905

Flumatinib mesylate 3 Publications Verification HHGV678 mesylate	Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀ values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model .

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, *c-Kit* and Bcr-abl .

HY-15463S1

Imatinib-d4 STI571 d₄; CGP-57148B d₄	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₄ (STI571-d₄) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-13904S

Flumatinib-d3 HHGV678-d₃	Isotope-Labeled Compounds Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .

HY-12010

BMS-599626 Hydrochloride 3 Publications Verification AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-18302

c-Kit-IN-5-1 1 Publications Verification	c-Kit	Inflammation/Immunology
c-Kit-IN-5 is potent inhibitor of *c-Kit, with IC₅₀s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit* over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties .

HY-15463S

Imatinib-d8 1 Publications Verification STI571-d₈; CGP-57148B-d₈	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-13342AS

Apatinib-d8 free base YN968D1-d8 free base	Src VEGFR Autophagy c-Kit RET	Cancer
Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC₅₀=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC₅₀s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .

HY-18179

AZD2932	PDGFR VEGFR FLT3 c-Kit	Cancer
AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3 and *c-Kit* with IC₅₀s of 8, 4, 7 and 9 nM in cell assay, respectively.

HY-10202A

Tandutinib hydrochloride 5 Publications Verification MLN518 hydrochloride; CT53518 hydrochloride	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits *c-Kit* and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .

HY-13645

Henatinib	VEGFR c-Kit PDGFR	Cancer
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of VEGFR-2, *c-kit, PDGFR* with IC₅₀ values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs) .

HY-10527C

Telatinib mesylate 1 Publications Verification Bay 57-9352 mesylate	VEGFR PDGFR c-Kit	Cancer
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and *c-Kit* inhibitor with IC₅₀s of 6 nM, 4 nM, 15 nM and 1 nM, respectively .

HY-16749R

Pexidartinib (Standard) PLX-3397 (Standard)	c-Fms c-Kit Apoptosis Reference Standards	Cancer
Pexidartinib (Standard) is the analytical standard of Pexidartinib. This product is intended for research and analytical applications. Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity .

HY-10208S

Pazopanib-d6 GW786034-d₆	Isotope-Labeled Compounds VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-108713A

Famitinib malate SHR1020 malate	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of *c-kit, VEGFR-2* and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .

HY-15463R

Imatinib (Standard) STI571 (Standard); CGP-57148B (Standard)	Reference Standards Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and *c-kit* kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-101219

VEGFR-IN-1	VEGFR c-Kit EGFR	Cancer
VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively .

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, *c-Kit, FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-10206A

Amuvatinib hydrochloride MP470 hydrochloride; HPK 56 hydrochloride	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET	Cancer
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant *c-Kit, PDGFRα, Flt3, c-Met* and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990851

Anti-c-Kit/CD117 Antibody (SR-1)	c-Kit	Inflammation/Immunology Cancer
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human *c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit* (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft .

HY-P990020

Eglatoprutug FSI-174	c-Kit	Others
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0419

Quercimeritrin 2 Publications Verification Quercetin-7-O-β-D-glucopyranoside	Flavonols Structural Classification Ginkgoaceae Classification of Application Fields Metabolic Disease Plants Compositae Endogenous metabolite Ginkgo biloba Human Gut Microbiota Metabolites Flavonoids Derris scandens Disease Research Fields Source Classification	Glycosidase c-Kit MMP VEGFR Aurora Kinase
Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC₅₀ of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer .

HY-W011873R

Palmitoleic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-15463S1

Imatinib-d4
Imatinib-d₄ (STI571-d₄) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC₅₀=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC₅₀s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10230S

Midostaurin-d5
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM .

HY-W705479

Pazopanib-d3 hydrochloride
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, *c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S2

Pazopanib-d3
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, *c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-15463S3

Imatinib-13C,d3

Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride . Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib . Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-10201S4

Sorafenib-d3 tosylate

Sorafenib-d₃ (Donafenib-d₃) tosylate is the deuterium labeled Sorafenib (HY-10201). Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-W751179

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks